Upstream Bio Reports Positive Phase 2 VALIANT Trial Results for Verekitug in Severe Asthma
UPB has more than doubled off its 52-week low of $5.14.
Summary
Upstream Bio reported positive Phase 2 VALIANT trial results for verekitug in severe asthma, meeting its primary endpoint with significant reductions in exacerbation rates and a favorable safety profile.
Key Events · Product Development and Regulatory · UPB
-
Phase 2 VALIANT Trial Met Primary Endpoint
Verekitug demonstrated statistically significant and clinically meaningful reductions in annualized asthma exacerbation rates (AAER) in severe asthma patients, meeting the primary endpoint of the VALIANT study.
-
Significant Efficacy Data
The 100mg q12w dose showed a 56% AAER reduction (p<0.0003), and the 400mg q24w dose showed a 39% AAER reduction (p<0.02). Both doses also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO).
-
Favorable Safety Profile
Verekitug was generally well tolerated across treatment groups, with a safety profile consistent with prior studies, and overall incidence of treatment-emergent adverse events (TEAEs) was similar across groups.
-
Strong Financial Position
The company reported preliminary unaudited cash, cash equivalents, and short-term investments of approximately $341.5 million as of December 31, 2025, which is expected to fund planned operations through 2027.
Analysis · UPB · Life Sciences
Upstream Bio announced highly positive top-line results from its Phase 2 VALIANT clinical trial for verekitug in severe asthma. The study successfully met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in annualized asthma exacerbation rates (AAER) across both tested dosing regimens. These results, coupled with improvements in lung function and biomarkers and a consistent safety profile, significantly de-risk the development of verekitug and provide a strong foundation for advancing to Phase 3 trials. The company also reported a solid cash position, extending its operational runway.
At the time of this filing, UPB was trading at $19.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $5.14 to $33.68. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.